Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  PDL BioPharma Inc    PDLI

PDL BIOPHARMA INC

(PDLI)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

PDL BioPharma : Announces Departure of CFO

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/25/2019 | 04:06pm EDT

INCLINE VILLAGE, Nev., June 25, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced the resignation of Chief Financial Officer, Peter Garcia, who will be leaving the Company effective August 15, 2019. He will continue in his role through the filing of the Company's second quarter 10-Q in August and is committed to ensure a smooth transition of duties.

Since joining PDL in May 2013, Mr. Garcia played an instrumental role in successfully completing the Company's convertible debt transactions, achieving an improved capital structure for the Company, and building a quality finance and accounting team.

"On behalf of the Company's board of directors and the management team, I'd like to thank Pete for his leadership and many contributions during his time at PDL," said Dominique Monnet, president and CEO of PDL. "Pete's legacy is positioning us for success as we execute our business strategy of building a portfolio of actively managed healthcare assets. We wish Pete well as he pursues his personal goals." The Company is retaining an executive search firm to lead the search for his replacement.

About PDL BioPharma, Inc.

PDL's mission is to improve the lives of patients and create value for our shareholders and our people by applying our capital and expertise for the successful development and commercialization of innovative therapeutics by our partner companies. We deliver on our mission by entering into strategic transactions involving innovative late clinical-stage or early commercial-stage therapeutics with attractive revenue growth potential.

NOTE: PDL, PDL BioPharma, the PDL logo and associated logos and the PDL BioPharma logo are trademarks or registered trademarks of, and are proprietary to, PDL BioPharma, Inc. which reserves all rights therein.

PDL BioPharma, Inc. (PRNewsFoto/PDL BioPharma, Inc.)

 

Cision
View original content to download multimedia:http://www.prnewswire.com/news-releases/pdl-biopharma-announces-departure-of-cfo-300874794.html

SOURCE PDL BioPharma, Inc.


© PRNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PDL BIOPHARMA INC
06/26PDL BIOPHARMA : Announces Departure of CFO June 25, 2019
AQ
06/25PDL BIOPHARMA, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
06/25PDL BIOPHARMA : Announces Departure of CFO
PR
06/24PDL BIOPHARMA, INC. : Change in Directors or Principal Officers, Submission of M..
AQ
06/10PDL BIOPHARMA, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/28PDL BIOPHARMA : to Participate in Jefferies 2019 Global Healthcare Conference
PR
05/21PDL BIOPHARMA, INC. : Regulation FD Disclosure, Financial Statements and Exhibit..
AQ
05/15PDL BIOPHARMA : to Participate at UBS Global Healthcare Conference
PR
05/09PDL BIOPHARMA : 1Q Earnings Snapshot
AQ
05/09PDL BIOPHARMA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
AQ
More news